Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Ovarian Neoplasms 3Mesothelioma, Malignant 3Solid Tumors 2Neoplasm Metastasis 2Disease Progression 2Small Cell Lung Carcinoma 1Sarcoma 1Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Solid Tumors 1

Interventions

Injections 25Carboplatin 17Docetaxel 14pembrolizumab 12Paclitaxel 11Bevacizumab 9durvalumab 8Cisplatin 8Nivolumab 6Fluorouracil 6trifluridine tipiracil drug combination 5tislelizumab 5linifanib 5Pemetrexed 5Oxaliplatin 5Leucovorin 5zimberelimab 4toripalimab 4talazoparib 4olaparib 4Itraconazole 4Irinotecan 4Gemcitabine 4Capecitabine 4tremelimumab 3sotorasib 3sintilimab 3fludarabine 3depatuxizumab 3atezolizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Solid Tumors × tumor necrosis factor-alpha, CNGRC fusion protein, human × Clear all
NCT00419328 2022-07-21

A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors

AGC Biologics S.p.A.

Phase 1 Completed
16 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡